Cover Image
Market Research Report

Cancer Drugs Market by Therapy for Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer and Other Cancer: Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 - 2021

Published by Zion Market Research Product code 630230
Published Content info 110 Pages
Delivery time: 2-3 business days
Price
Back to Top
Cancer Drugs Market by Therapy for Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer and Other Cancer: Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 - 2021
Published: December 7, 2016 Content info: 110 Pages
Description

The report covers forecast and analysis for the cancer drugs market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based revenue (USD Billion). The study includes drivers and restraints for the cancer drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the cancer drugs market on a global level.

In order to give the users of this report a comprehensive view on the cancer drugs market, we have include competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Therapy segments and cancer type segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new Therapy launch, agreements, partnerships, collaborations joint ventures, research development, Therapy and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, Therapy portfolio of various companies along with patent analysis (2011-2016) bifurcated into the patent trend, patent share by company and patent analysis according to the region.

The study provides a decisive view on the cancer drugs market by segmenting the market based on therapy, cancer type, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Based on therapy the market is segmented into immunotherapy, targeted therapy, chemotherapy, hormone therapy and others. Key cancer type covered under this study includes breast cancer, blood cancer, gastrointestinal cancer, prostate cancer, skin cancer, lung cancer and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for cancer drugs based on individual therapy and cancer in all the regions and countries.

The report also includes detailed profiles of end players such as Bayer, GlaxoSmithKline, Novartis, Sanofi and Pfizer, Amgen, Merck, Bristol-Myers Squibb, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche Ltd, Boehringer Ingelheim GmbH, Johnson and Johnson and Teva Pharmaceuticals among others.

This report segments the global cancer drugs market as follows:

Global Cancer Drugs Market: Therapy Segment Analysis

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Hormone Therapy
  • Others

Global Cancer Drugs Market: Cancer Type Segment Analysis.

  • Breast Cancer
  • Blood Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Skin Cancer
  • Lung Cancer
  • Others

Global Cancer Drugs Market: Regional Segment Analysis

  • North America
  • U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Table of Contents

Table of Contents

Chapter 1. Introduction

  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology

Chapter 2. Executive Summary

  • 2.1. Global cancer drugs market, 2015 2021 (USD Billion)
  • 2.2. Global cancer drugs market : Snapshot

Chapter 3. Cancer drugs Market Dynamics

  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global cancer drugs market drivers: Impact analysis
    • 3.2.2. Rising incidences of target disease
    • 3.2.3. Expiration of patents
  • 3.3. Market restraints
    • 3.3.1. Global cancer drugs market restraints: Impact analysis
    • 3.3.2. High price of drug development
  • 3.4. Opportunities
    • 3.4.1. Increasing focus on personalized medicine
  • 3.5. Porters five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. Threat from new entrants
    • 3.5.4. Threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by therapy segment
    • 3.6.2. Market attractiveness analysis, by cancer type segment
    • 3.6.3. Market attractiveness analysis, by regional segment

Chapter 4. Global Cancer Drugs Market Competitive Landscape

  • 4.1. Company Market Share Analysis
    • 4.1.1. Global cancer Drugs market: company market share, 2015
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions Mergers
    • 4.2.2. New Therapy Launch
    • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
    • 4.2.4. Research and Development, Therapy and Regional Expansion
  • 4.3. Price Trend Analysis
  • 4.4. Therapy Portfolio
  • 4.5. Patent Analysis (2011-2016)
    • 4.5.1. Patent Trend
    • 4.5.2. Patent Share by company
    • 4.5.3. By Region

Chapter 5. Global Cancer drugs Market Therapy Segment Analysis

  • 5.1. Global cancer drugs market: Therapy overview
    • 5.1.1. Global cancer drugs market revenue share, by Therapy, 2015 and 2021
  • 5.2. Immunotherapy
    • 5.2.1. Global Immunotherapy market , 2015 2021(USD Billion)
  • 5.3. Targeted Therapy
    • 5.3.1. Global Targeted Therapy market , 2015 2021(USD Billion)
  • 5.4. Chemotherapy
    • 5.4.1. Global Chemotherapy market , 2015 2021(USD Billion)
  • 5.5. Hormone Therapy
    • 5.5.1. Global Hormone Therapy market , 2015 2021(USD Billion)
  • 5.6. Others
    • 5.6.1. Global Others market , 2015 2021(USD Billion)

Chapter 6. Global Cancer Drugs Market Cancer type Segment Analysis

  • 6.1. Global cancer drugs market: Cancer type overview
    • 6.1.1. Global cancer drugs market revenue share, by cancer type, 2015 and 2020
  • 6.2. Breast Cancer
    • 6.2.1. Global cancer drugs market for Breast Cancer, 2015 2021 (USD Billion)
  • 6.3. Blood Cancer
    • 6.3.1. Global cancer drugs market for Blood Cancer, 2015 2021(USD Billion)
  • 6.4. Gastrointestinal Cancer
    • 6.4.1. Global cancer drugs market for Gastrointestinal Cancer, 2015 2021 (USD Billion)
  • 6.5. Prostate Cancer
    • 6.5.1. Global cancer drugs market for Prostate Cancer, 2015 - 2021(USD Billion)
  • 6.6. Skin Cancer
    • 6.6.1. Global cancer drugs market for Skin Cancer, 2015 - 2021(USD Billion)
  • 6.7. Lung Cancer
    • 6.7.1. Global cancer drugs market for Lung Cancer, 2015 - 2021(USD Billion)
  • 6.8. Others
    • 6.8.1. Global cancer drugs market for other cancer type , 2015 2021 (USD Billion)

Chapter 7. Global Cancer drugs Market Regional Segment Analysis

  • 7.1. Global cancer drugs market: Regional overview
    • 7.1.1. Global cancer drugs market revenue share, by region, 2015 and 2021
  • 7.2. North America
    • 7.2.1. North America cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
    • 7.2.2. North America cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
    • 7.2.3. U.S.
      • 7.2.3.1. U.S. cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.2.3.2. U.S. cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
    • 7.3.2. Europe cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.3.3.2. Germany cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.3.4.2. France cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
    • 7.3.5. UK
      • 7.3.5.1. UK cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.3.5.2. UK cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific cancer drugs market revenue, by Therapy, 2015 2021, (USD Billion)
    • 7.4.2. Asia Pacific cancer drugs market revenue, by cancer type, 2015 2021, (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.4.3.2. China cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
    • 7.4.4. Japan
      • 7.4.4.1. Japan cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.4.4.2. Japan cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
    • 7.4.5. India
      • 7.4.5.1. India cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.4.5.2. India cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
    • 7.5.2. Latin America cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)
    • 7.5.3. Brazil
      • 7.5.3.1. Brazil cancer drugs market revenue, by Therapy, 2015 2021(USD Billion)
      • 7.5.3.2. Brazil cancer drugs market revenue, by cancer type, 2015 2021 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa cancer drugs market revenue, by Therapy, 2015 2021 (USD Billion)
    • 7.6.2. Middle East and Africa cancer drugs market revenue, by cancer type, 2015 2021(USD Billion)

Chapter 8. Company Profile

  • 8.1. Bayer
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Therapy portfolio
    • 8.1.4. Business strategy
    • 8.1.5. Recent developments
  • 8.2. GlaxoSmithKline
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Therapy portfolio
    • 8.2.4. Business strategy
    • 8.2.5. Recent developments
  • 8.3. Novartis
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Therapy portfolio
    • 8.3.4. Business strategy
    • 8.3.5. Recent developments
  • 8.4. Sanofi
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Therapy portfolio
    • 8.4.4. Business strategy
    • 8.4.5. Recent developments
  • 8.5. Pfizer
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Therapy portfolio
    • 8.5.4. Business strategy
    • 8.5.5. Recent developments
  • 8.6. Amgen
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Therapy portfolio
    • 8.6.4. Business strategy
    • 8.6.5. Recent developments
  • 8.7. Merck
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Therapy portfolio
    • 8.7.4. Business strategy
    • 8.7.5. Recent developments
  • 8.8. Bristol-Myers Squibb
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Therapy portfolio
    • 8.8.4. Business strategy
    • 8.8.5. Recent developments
  • 8.9. Celgene Corporation
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Therapy portfolio
    • 8.9.4. Business strategy
    • 8.9.5. Recent developments
  • 8.10. Ariad Pharmaceuticals
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Therapy portfolio
    • 8.10.4. Business strategy
    • 8.10.5. Recent developments
  • 8.11. Eli Lilly
    • 8.11.1. Overview
    • 8.11.2. Financials
    • 8.11.3. Therapy portfolio
    • 8.11.4. Business strategy
    • 8.11.5. Recent developments
  • 8.12. Hoffmann-La Roche Ltd
    • 8.12.1. Overview
    • 8.12.2. Financials
    • 8.12.3. Therapy portfolio
    • 8.12.4. Business strategy
    • 8.12.5. Recent developments
  • 8.13. Boehringer Ingelheim GmbH
    • 8.13.1. Overview
    • 8.13.2. Financials
    • 8.13.3. Therapy portfolio
    • 8.13.4. Business strategy
    • 8.13.5. Recent developments
  • 8.14. Johnson and Johnson
    • 8.14.1. Overview
    • 8.14.2. Financials
    • 8.14.3. Therapy portfolio
    • 8.14.4. Business strategy
    • 8.14.5. Recent developments
  • 8.15. Teva Pharmaceuticals
    • 8.15.1. Overview
    • 8.15.2. Financials
    • 8.15.3. Therapy portfolio
    • 8.15.4. Business strategy
    • 8.15.5. Recent developments
Back to Top